Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma

Oral Oncology

Volumn 47, Issue 6, 2011, Pages 510-516

  Kokko, Linda Lotta ^a   Hurme, Saija ^b   Maula, Sanna Mari ^c   Alanen, Kalle ^b   Grénman, Reidar ^a   Kinnunen, Ilpo ^a   Ventelä, Sami ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

CD44; Head and neck cancer; Head and neck squamous cell carcinoma; HNSCC; Smoking; Staging; TNM

Indexed keywords

ALCOHOL; ANTIBODY; CD44 ANTIBODY; CELL MARKER; HERMES ANTIGEN; PARAFFIN; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR LOCALIZATION;

ALCOHOL DRINKING; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PROGNOSIS; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 79958054545     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.03.026     Document Type: Article

References (39)

1. Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J Biol Chem 2002;277(7):4589-92. (Pubitemid 34968484)
2. Wang SJ, Bourguignon LY. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006;132(7):771-8. (Pubitemid 44086442)
3. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009;119(8):1518-30.
4. Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J Biol Chem 2001;276(52):48679-92.
5. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46(7):1271-7.
6. Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004;10(14):4822-30. (Pubitemid 38955536)
7. Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998;58(6):1108-10. (Pubitemid 28183192)
8. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 2000;192(4):427-32.
9. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 isoforms in prognosis of breast cancer. Lancet 1995;346(8973):502.
10. Manten-Horst E, Danen EH, Smit L, Snoek M, Le Poole IC, Van Muijen GN, et al. Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential. Biochem Biophys Res Commun 1995;214(1):137-44.
11. Miwa T, Watanabe A, Yamada Y, Shino Y, Yamada T, Yamashita J, et al. Progression in gastric carcinoma relative to the ratio of CD44 epithelial variant transcript to CD44 hematopoietic variant transcript. Cancer 1996;77(1):25-9. (Pubitemid 26002733)
12. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63(8):1920-6. (Pubitemid 36460859)
13. Situ, Long, Lin, Zhu, Wang, Zhang. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol 2010;136(8):1213-9.
14. González-Moles MA, Gil-Montoya JA, Ruiz-Avila I, Esteban F, Delgado-Rodriguez M, Bascones-Martinez A. Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. Oncol Rep 2007;18:389-96.
15. Stoll C, Baretton G, Soost F, Terpe HJ, Domide P, Löhrs U. Prognostic importance of the expression of CD44 splice variants in oral squamous cell carcinomas. Oral Oncol 1999;35:484-9. (Pubitemid 29386784)
16. Shah J, Gil Z. Current concepts in management of oral cancer - Surgery. Oral Oncology 2008;45:394-401.
17. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
18. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349(22):2091-8. (Pubitemid 37464533)
19. Marur S, Forastiere AA. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell carcinoma. Curr Opin Oncol 2010;22(3):206-11.
20. Lin JT, Chang TH, Chang CS, Wang WH, Su BW, Lee KD, et al. Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol 2010;46(5):e29-33.
21. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, et al. Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 2010;30(1):253-9.
22. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010;176(5):2131-8.
23. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK. Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 2009;14(1):27.
24. van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brakenhoff RH. Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int J Cancer 1999;82(6):837-45. (Pubitemid 29384335)
25. Kanke M, Fujii M, Kameyama K, Kanzaki J, Tokumaru Y, Imanishi Y, et al. Role of CD44 variant exon 6 in invasion of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2000;126(10):1217-23.
26. de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010;16:5329-38.
27. Carinci F, Stabellini G, Calvitti M, Pelucchi S, Targa L, Farina A, et al. CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma. J Craniofac Surg 2002;13:85-9. (Pubitemid 34873952)
28. Uwa N, Kataoka TR, Torii I, Sato A, Nishigami T, Song M M, et al. CD44 expression is related to poor prognosis of hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 2010.
29. Tu LC, Foltz G, Lin E, Hood L, Tian Q. Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther 2009;4:147-53.
30. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
31. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem cells 2009;27:1006-20.
32. Okamoto A, Chikamatsu K, Sakakura K, Hatsushika K, Takahashi G, Masuyama K. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009;45(7):633-9.
33. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carsinoma. Proc Natl Acad Sci U S A 2007;104(3):973-8. (Pubitemid 46154721)
34. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker nanog, stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
35. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ. Cancer stem cells: how can we target them? Curr Med Chem 2008;15:3171-84.
36. Mayer S, Zur Hausen A, Watermann DO, Stamm S, Jäger M, Gitsch M, Stickeler M. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 2008;134(11):1229-35.
37. Yu Q, Toole BP, Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 1997;186(12):1985-96. (Pubitemid 28013682)
38. Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco-related lesions:conclusions of an international symposium held in Uppsala, Sweden, May 18-21, 1994. J Oral Pathol Med 1996;25:49-54.
39. Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biörklund A, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer 1998;82:1367-75. (Pubitemid 28155400)